# Filing Detail

Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001171843-20-001853
Filing Date
2020-03-19
Accepted
2020-03-19 16:15:17
Documents
4
Period of Report
2020-05-12

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PRELIMINARY PROXY STATEMENT | pre14a_032020.htm | PRE 14A | 965063
2 | GRAPHIC | logo.jpg | GRAPHIC | 5374
3 | GRAPHIC | proxy_1.jpg | GRAPHIC | 1782316
4 | GRAPHIC | proxy_2.jpg | GRAPHIC | 958511
| Complete submission text file | 0001171843-20-001853.txt |  | 4748185

Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 000-23186 | Film No.: 20728703
SIC: 2836 Biological Products, (No Diagnostic Substances)